(TARS) –
-
Form 8-K Tarsus Pharmaceuticals, For: Apr 19
-
Tarsus Pharmaceuticals (TARS) Refinances Existing Debt with $200M Non-dilutive Financing
-
Tarsus Pharmaceuticals (TARS) Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
-
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
-
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
-
Form 144 Tarsus Pharmaceuticals, Filed by: Trevejo Jose M.
-
Form 144 Tarsus Pharmaceuticals, Filed by: Trevejo Jose M.
-
Form 4 Tarsus Pharmaceuticals, For: Mar 15 Filed by: Mottiwala Aziz
-
Form 4 Tarsus Pharmaceuticals, For: Mar 15 Filed by: Wahl Bryan
-
Form 4 Tarsus Pharmaceuticals, For: Mar 15 Filed by: Azamian Bobak R.
-
Form 4 Tarsus Pharmaceuticals, For: Mar 15 Filed by: Whitfield Dianne C.
-
Form 4 Tarsus Pharmaceuticals, For: Mar 15 Filed by: Neervannan Seshadri
-
Form 144 Tarsus Pharmaceuticals, Filed by: Azamian Bobak R.
-
Form 144 Tarsus Pharmaceuticals, Filed by: Whitfield Dianne C.
-
Form 144 Tarsus Pharmaceuticals, Filed by: Wahl Bryan
-
Form 144 Tarsus Pharmaceuticals, Filed by: Neervannan Seshadri
-
Form 144 Tarsus Pharmaceuticals, Filed by: Mottiwala Aziz
-
Form 4 Tarsus Pharmaceuticals, For: Mar 07 Filed by: Azamian Bobak R.
-
Form 4 Tarsus Pharmaceuticals, For: Mar 07 Filed by: Wahl Bryan
-
Form 4 Tarsus Pharmaceuticals, For: Mar 07 Filed by: Mottiwala Aziz
-
Form 4 Tarsus Pharmaceuticals, For: Mar 07 Filed by: Whitfield Dianne C.
-
Form 4 Tarsus Pharmaceuticals, For: Mar 07 Filed by: Farrow Jeffrey S
-
Form 4 Tarsus Pharmaceuticals, For: Mar 07 Filed by: Neervannan Seshadri
-
Tarsus Pharmaceuticals (TARS) PT Raised to $44 at Jefferies, 'Launch Progressing Well'
-
Tarsus to Participate at Upcoming Investor Conferences
-
Form 8-K Tarsus Pharmaceuticals, For: Mar 05
-
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
-
Form 8-K Tarsus Pharmaceuticals, For: Feb 29
-
Form 424B5 Tarsus Pharmaceuticals,
-
Tarsus Pharmaceuticals (TARS) Announces Pricing of $100.0 Million Public Offering
-
Tarsus Announces Pricing of $100.0 Million Public Offering
-
Form 424B5 Tarsus Pharmaceuticals,
-
Tarsus Pharmaceuticals (TARS) Files Mixed Shelf
-
Tarsus Pharmaceuticals (TARS) Announces Proposed $100M Share Offering
-
Tarsus Announces Proposed $100.0 Million Public Offering
-
Form S-3ASR Tarsus Pharmaceuticals,
-
Tarsus Pharmaceuticals (TARS) PT Raised to $59 at Oppenheimer
-
Tarsus Pharmaceuticals (TARS) PT Raised to $60 at BofA Securities
-
Tarsus Pharmaceuticals (TARS) PT Raised to $50 at Barclays
-
Form S-8 Tarsus Pharmaceuticals,
-
Form 10-K Tarsus Pharmaceuticals, For: Dec 31
-
Tarsus Pharmaceuticals, Inc. (TARS) Tops Q4 EPS by 7c
-
Form 8-K Tarsus Pharmaceuticals, For: Feb 27
-
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
-
Tarsus Pharmaceuticals (TARS) Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
-
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
-
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
-
Form SC 13G/A Tarsus Pharmaceuticals, Filed by: TANG CAPITAL PARTNERS LP
-
Form SC 13G/A Tarsus Pharmaceuticals, Filed by: Cormorant Asset Management, LP
-
Form SC 13G/A Tarsus Pharmaceuticals, Filed by: RTW INVESTMENTS, LP
Back to TARS Stock Lookup
